An Open-label, Multiple Dose Study to Assess Safety, Tolerability and Pharmacokinetics of Different Multiple Doses of BI 207127 BID Administered Orally for 9 Days (Part 1) and Multiple Doses of BI 207127 Combined With Faldaprevir Administered Orally for 16 Days (Part 2) in Healthy Male and Female Subjects
Phase of Trial: Phase I
Latest Information Update: 12 Apr 2016
At a glance
- Drugs Deleobuvir (Primary) ; Faldaprevir
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 07 Apr 2016 Treatment arms (3 to 1), Trial focus (PK to PK and AR) as well as the study design changed as reported by ClinicalTrials.gov record.
- 17 Apr 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 03 Apr 2013 Planned End Date changed from 1 Mar 2013 to 1 Apr 2013 as reported by ClinicalTrials.gov.